Virginia

Start Pallas's online intake — it takes about 5 minutes and covers your health history, goals, and current medications. A Virginia-licensed clinician reviews it, and because Virginia allows asynchronous-first care for non-controlled medications like GLP-1s, that review can happen by secure message without a scheduled video call, unless your history calls for one. If a GLP-1 is clinically appropriate, your clinician prescribes it, and a US-licensed pharmacy ships your medication to any Virginia address in a few business days.

The process is the same as for semaglutide — complete Pallas's online intake, and a Virginia-licensed clinician reviews it, asynchronously in most cases, since Virginia allows telehealth providers to establish care and prescribe without a live video visit when the standard of care is met. If appropriate, your clinician can prescribe compounded tirzepatide, prepared per-patient by a US-licensed §503A compounding pharmacy based on a documented clinical rationale, or an FDA-approved brand-name option like Zepbound^® or Mounjaro^®, through the same intake. These are distinct products with different regulatory status; your clinician will explain which fits you.

No — Virginia allows asynchronous-first care. A Virginia-licensed provider can review your intake by secure message and, if appropriate, prescribe semaglutide without a scheduled video call, as long as the standard of care is met. Your provider may request a video visit or additional information only if your history calls for it.

Yes — compounded semaglutide is available to eligible Virginia residents through licensed telehealth. It is prepared per-patient by US-licensed compounding pharmacies under FDCA §503A, and a Virginia-licensed clinician must prescribe it based on a documented, patient-specific clinical rationale. Pallas works only with U.S. state-licensed 503A and 503B compounding pharmacies and serves Virginia with free shipping. FDA-approved brand-name options like Wegovy^® and Zepbound^® are also available through the same intake.

Yes, within their scope of practice. Virginia nurse practitioners prescribe under a written practice agreement with a patient care team physician, and gain autonomous practice after three years of full-time clinical experience. Because semaglutide and tirzepatide are not controlled substances, Virginia permits prescribing them through telehealth without an in-person visit. Every Pallas clinician who treats Virginia patients holds an active Virginia license and prescribes within these rules.

Several licensed telehealth platforms serve Virginia residents seeking compounded semaglutide. Before choosing one, verify that its clinicians are licensed in Virginia, that it works with US-licensed §503A compounding pharmacies, and that it holds LegitScript Healthcare Merchant Certification — you can check any platform's certification status in LegitScript's public database. Pallas serves Virginia residents and is LegitScript Healthcare Merchant Certified.

Virginia Medicaid (Cardinal Care) covers certain GLP-1s for FDA-approved diabetes indications with prior authorization. Coverage for weight-management indications is limited. Compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service, so Medicaid rules do not affect our pricing.

Most Virginia patients receive their medication within 2–3 business days of the pharmacy filling the prescription. Northern Virginia, Richmond, and Hampton Roads typically ship fastest; Shenandoah Valley and rural southwestern ZIP codes may take an extra day.

Pallas is a cash-pay telehealth service — there is no insurance to bill. Your Pallas Membership covers your clinician's review, ongoing check-ins, and care-team messaging; the medication is billed separately and ships free to your Virginia address, only when a clinician prescribes it. You see your full price during intake before you pay anything — no surprise renewal markups. The price is the same whether you are in Northern Virginia, Hampton Roads, or a rural Virginia ZIP code.

Eligibility is always decided by a Virginia-licensed clinician after reviewing your full intake, never by an automated quiz. In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.

Brand-name medications — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your Virginia-licensed provider.

Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A clinician licensed by the Virginia Board of Medicine reviews it asynchronously in most cases — no live video required — and may follow up by secure message or request labs if your history calls for it. A license from another state is never sufficient; every Pallas clinician who treats Virginia patients is individually licensed in Virginia. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any Virginia address, usually within a few business days.

Pallas care is ongoing, not a one-time script. Your plan renews on a regular cadence so your medication arrives before you run out, and your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects. You can message your care team, change your plan, or cancel anytime from your patient portal — no phone calls or retention hoops.

Compounded semaglutide injection through Pallas is $139 first month, then $597 every 12 weeks ($199/mo average), charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Virginia address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Compounded tirzepatide injection through Pallas is $179 first month, then $897 every 12 weeks ($299/mo average), charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Virginia address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Yes. FDA-approved Wegovy^® and Zepbound^® for chronic weight management — plus Ozempic^® and Mounjaro^® for type 2 diabetes — are available to Virginia patients cash-pay from $1069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in Virginia during intake.

Coverage of GLP-1 medications for weight loss through Cardinal Care is limited. Virginia Medicaid (Cardinal Care) covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited. Compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service — we do not bill Cardinal Care or private insurance. Pricing is flat and disclosed up front; the cost questions on this page carry current plan terms.

You have two cash-pay paths in Virginia, and neither requires insurance. One: stay on FDA-approved Wegovy^® or Zepbound^® at flat cash-pay pricing from $1069/mo. Two: if a clinician licensed in Virginia determines it is clinically appropriate for you, a compounded semaglutide plan ($139 first month, then $597 every 12 weeks ($199/mo average), charged once a clinician prescribes. Cancel anytime.) or compounded tirzepatide plan ($179 first month, then $897 every 12 weeks ($299/mo average), charged once a clinician prescribes. Cancel anytime.), prepared per-patient by a US-licensed pharmacy under FDCA §503A. There is no gap in care: start the online intake, tell your clinician what you take now and your current dose, and they factor that history into your treatment plan and starting dose. Our guide to switching GLP-1 telehealth providers on the Pallas blog covers records, timing, and what to expect.

That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound^® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy^® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks. Wegovy^®'s maximum dose is now 7.2 mg weekly, which was not studied in SURMOUNT-5; in the separate STEP UP trial it reached 18.7% average weight loss over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in Virginia weighs your history, goals, and budget to recommend a starting point.